Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.

Abstract

AIM Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were established in mainly Caucasian populations. Because of inter-ethnic genotype variability of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS In this single-arm study, Taiwanese patients… (More)
DOI: 10.1111/ajco.12659

Topics

Cite this paper

@article{Chou2017EfficacySA, title={Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.}, author={Wen-Chien Chou and S Z Yeh and L. T. Hsiao and Sheng-Fung Lin and Yeu-Chin Chen and Tsai-Yun Chen and Eric Laille and Anoula Galettis and Qian Dong and Steve Songer and Craig Beach}, journal={Asia-Pacific journal of clinical oncology}, year={2017}, volume={13 5}, pages={e430-e439} }